Scientists at Weill Cornell Medicine have made a groundbreaking discovery, revealing a critical mechanism behind the uncontrolled growth of prostate cancer. Published in Nature Communications, their study sheds light on how prostate cancer manipulates a key protein, the androgen receptor, to fuel its relentless proliferation.
The androgen receptor normally plays a dual role in prostate cells:

• It acts as a growth “accelerator.”
• It also functions as a growth “brake.”

In prostate cancer, this delicate balance is disrupted. The cancer effectively “hijacks” the androgen receptor, forcing it to favor the “accelerator” function while releasing the “brake,” leading to uninhibited tumor growth.
The research team, delved deeper into this hijacking process. They focused on a previously overlooked aspect: the loss of the androgen receptor’s binding to certain DNA sites. Their hypothesis was that these abandoned binding sites might actually hold the key to suppressing cancer cell growth.

To test this theory, they created a panel of artificial proteins that mimicked the DNA-binding section of the androgen receptor. This allowed them to systematically investigate the effects of activating or suppressing different genes controlled by the androgen receptor.
Their meticulous work uncovered a crucial finding: a family of genes that can effectively halt the growth of prostate cancer cells.

Intriguingly, activating these same genes in healthy prostate cells had no effect. This suggests that cancer cells specifically rewire these genetic pathways to unleash their growth potential.
This breakthrough has far-reaching implications for prostate cancer management:

• New Diagnostic Tests: The study revealed a correlation between the expression levels of the normal androgen receptor program in tumor cells and patient prognosis, treatment response, and overall outcomes. This knowledge can pave the way for the development of new diagnostic tests that provide more accurate predictions and guide personalized treatment strategies.
• Novel Therapeutic Targets: The identification of these growth-halting genes opens up exciting possibilities for developing innovative therapies. Scientists envision drugs that could reactivate the normal regulatory program in prostate cancer cells, effectively putting the brakes back on tumor growth.

This study marks a significant advancement in our understanding of prostate cancer. It provides a new lens through which to view this complex disease and offers hope for more effective diagnostics and treatments in the future.

Source.